预约演示
更新于：2025-02-27
Mirabegron
米拉贝隆
更新于：2025-02-27
概要
基本信息
药物类型 小分子化药 |
别名 Betmiga PR、Mirabegron (USAN/JAN)、Myrbetriq Granules + [8] |
作用机制 GP IIb/IIIa拮抗剂(糖蛋白 IIb/IIIa拮抗剂) |
治疗领域 |
最高研发阶段批准上市 |
首次获批日期 日本 (2011-07-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H24N4O2S |
InChIKeyPBAPPPCECJKMCM-IBGZPJMESA-N |
CAS号223673-61-8 |
关联
239
项与 米拉贝隆 相关的临床试验NCT05713799
Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity
NCT06791460
Pegylated Liposomal Doxorubicin Plus Adebrelimab with or Without Mirabegron in Relapsed Ovarian Cancer: a Randomized, Controlled, Open-label Trial
NCT06803030
A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial
100 项与 米拉贝隆 相关的临床结果
登录后查看更多信息
100 项与 米拉贝隆 相关的转化医学
登录后查看更多信息
100 项与 米拉贝隆 相关的专利（医药）
登录后查看更多信息
1,368
项与 米拉贝隆 相关的文献（医药）2025-02-01NEUROUROLOGY AND URODYNAMICS
Patient Reported Outcomes Due to Bladder Neck Obstruction in Women Treated With Botulinum Toxin A Injection
Article
作者: Pettijohn, Dyer ; Walia, Jessmehar ; Rodriguez, Priscilla ; De, Elise J. B. ; Roberts, Brittany Lee ; Bibicheff, Darrel
ABSTRACT:
Introduction:
Primary bladder neck obstruction (BNO) occurs when the bladder neck fails to open during voiding, causing urinary symptoms despite no anatomic obstruction. The cause of BNO is unclear but may involve neurogenic dysregulation related to the sympathic nervous system such as upper motor neuron lesion or peripheral autonomic neuropathy (small fiber neuropathy (SFN)). Another etiology can incuded increased sympathetic tone secondary to anxiety or stress conditons. Botulinum toxin A (BoNT‐A) to the bladder neck has been used in our practice to treat women with BNO who failed conventional therapies (alpha blockers, relaxation strategies). This is the first report of patient‐reported outcomes after BoNT‐A treatment in women with pelvic pain and BNO.
Materials and Methods:
We included female patients with pelvic pain and BNO who received BoNT‐A to the bladder neck between January 2022 and March 2023, and mailed self‐reported outcome questionnaires. The primary outcome was the Global Response Assessment (GRA); secondary outcomes included pain scores on the Visual Analogue Scale (VAS) and symptom checklists. BNO was diagnosed using Nitti Criteria (high bladder pressure, low flow in bladder neck on video urodynamics), supplemented by additional criteria (e.g., high voiding pressure, prolonged attempts, Valsalva effort, and cystoscopic evidence or symptoms related to BNO). Urodynamic studies followed International Continence Society standards. Additionally, due to BNO's association with SFN, patient history of biopsy‐confirmed SFN was recorded.
Results:
Our inclusion criteria was satisfied among 18 patietns, with 17 completing the questionnaire. Out of those, 14 patients (77%) reported improvement on the GRA, with an average VAS of 8.3 (“Very Helpful”). The most commonly improved symptoms were feeling of incomplete emptying, difficulty starting stream, urethral burning, pain with urination, and pelvic pain. Postoperative symptom flares were reported in six patients for an average of 16 days. All six patients with biopsy‐confirmed SFN showed significant improvement (VAS 8.7). Total of 14 patients (77%) indicated they would repeat the procedure.
Conclusions:
BoNT‐A to the bladder neck significantly improved pelvic pain and refractory hesitancy in women with bladder neck obstruction, especially in those with small fiber neuropathy. Symptom flares are common, but did not reduce interest in repeated treatments, and scheduling injections before symptom recurrence may mitigate these flares.
2025-02-01NEUROUROLOGY AND URODYNAMICS
Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines, and Therapy Utilization Patterns
Article
作者: Enemchukwu, Ekene A. ; S. Burton, Claire ; Syan, Raveen ; Gunamany, Susanna ; Sinclair, Shada ; Zhang, Chiyuan A. ; Mohamud, Hodan
ABSTRACT:
Introduction:
Overactive bladder (OAB) is a chronic condition with significant financial and health‐related consequences. Guidelines and treatment pathways were created to optimize care and provide a clinical framework for diagnosing and managing OAB. However, the impact of these efforts and patterns of medical treatment for OAB are poorly understood. Therefore, we sought to evaluate overall trends in therapy utilization before and after the 2014 American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) OAB guideline amendment and publication of the OAB clinical care pathway in 2016.
Methods:
In this retrospective cohort study, we analyzed data from Optum, a national administrative health and pharmacy claims database, between 2013 and 2018. All adult patients diagnosed with idiopathic OAB were identified by the International Classification of Diseases 9th and 10th Revision codes. Oral OAB therapies were identified using National Drug Codes, while third‐line therapy procedures, onabotulinumtoxinA (BTX), sacral neuromodulation (SNM), and percutaneous tibial nerve stimulation (PTNS), were identified using Current Procedural Terminology (CPT) codes. The study's primary outcome was the annual number of OAB prescriptions filled by pharmacotherapy class and the number of minimally invasive therapies performed during the study period. The secondary outcome was the association between OAB therapy utilization and various clinical and sociodemographic factors. Patterns of care were analyzed from 2013 to 2018, and initial treatment with each therapy was collected, excluding repeat procedures from the analysis.
Results:
1 825 782 patients were included in the study. The mean age was 61.1 ± 16.7 years, and 1 071 420 patients were female (58.7%). The number of new OAB diagnoses increased by 369% from 2013 to 2017. During the 6‐year study period, 347 052 (19%) patients were treated with oral and/or third‐line therapies. The overall number of oral medications prescribed peaked in 2016, followed by a 17% decline between 2016 and 2018. In 2013, the two most prescribed oral medications were oxybutynin (46%) and solifenacin (31.8%). By 2018, mirabegron (18.5%) surpassed solifenacin (16.5%), with oxybutynin still accounting for most prescriptions written (55%). Eighty percent of all initial mirabegron prescriptions were filled by patients over the age of 65. The rate of third‐line therapy procedures almost doubled between 2013 and 2018 (9–17 procedures per 1000 OAB patients, p < 0.001).
Conclusions:
Following the publication of the first OAB guidelines, there was an increase in OAB diagnoses, followed by a decrease in anticholinergic medication use, and a rise in beta‐3 agonist utilization in patients over 65 years old. Additionally, there was greater adoption of third‐line OAB therapies. These trends indicate that OAB therapy guidelines and clinical practice pathways may influence treatment patterns. Given the recent publication of the OAB guidelines, further studies are necessary to assess their impact on therapy utilization patterns.
2025-02-01BIOMEDICINE & PHARMACOTHERAPY
Neuroprotective role of mirabegron: Targeting beta-3 adrenergic receptors to alleviate ulcerative colitis-associated cognitive impairment
Article
作者: El-Maraghy, Nabila ; Mansour, Suzan ; Abdallah, Dalaal M ; El-Abhar, Hanan S ; Wadie, Walaa ; Nasser, Salma
While cognitive impairment has been documented in ulcerative colitic patients, the possible influence of central β3-adrenergic receptor (β3-AR) signaling on this extraintestinal manifestation remains unclear. Previously, we identified an imperative role for mirabegron (MA) as an agonist of β3-AR, in decreasing the BACE-1/beta-amyloid (Aβ) cue in the colons of UC rats. Consequently, we investigated its therapeutic potential for alleviating cognitive impairment associated with UC. To fulfil our aim, rats administered iodoacetamide were treated with the β3-AR agonist (MA) alone, with the antagonist (SR59230A) for 8 days, or kept untreated. The animals' behavior (MWM and NOR tests) and hippocampal structure were assessed. Mechanistically, necroptosis, ER stress (ERS), Aβ-amyloidosis, inflammation/oxidative burden, and gut/BBB dysfunction were analyzed. Post-administration of MA improved weight gain, colon/hippocampal structures, and memory. Additionally, it inhibited serum levels of lipopolysaccharide and Annexin-1, indicating recovered gut and BBB integrity. MA turned off the pathogenic BACE-1/Aβ axis in the hippocampus, necroptosis trajectory (TNFR-1/RIPK1/RIPK3/MLKL), and the IRE-1α/JNK signal. Moreover, MA enhanced the transcription factor PPAR-γ, decreased NF-κΒ/TNF-α inflammatory hub, and modulated the redox imbalance by decreasing malondialdehyde and increasing catalase. Notably, MA's behavioral, structural, and molecular beneficial actions were hindered by the pre-administration of SR59230A. From a novel standpoint, we recognized the β3-AR as a therapeutic target for UC-associated cognitive impairment in the hippocampus. In this context, the aptitude of MA to inhibit UC-induced hippocampal amyloidogenesis, alongside its anti-necroptotic, anti-ERS, anti-inflammatory, and antioxidant effects, contribute to these central enhancements, while also regulating permeability in both gut and BBB barriers.
100 项与 米拉贝隆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 神经源性逼尿肌过度活动 | 欧盟 | 2024-09-05 | |
| 神经源性逼尿肌过度活动 | 冰岛 | 2024-09-05 | |
| 神经源性逼尿肌过度活动 | 列支敦士登 | 2024-09-05 | |
| 神经源性逼尿肌过度活动 | 挪威 | 2024-09-05 | |
| 膀胱过度活动症综合征 | 欧盟 | 2012-12-20 | |
| 膀胱过度活动症综合征 | 冰岛 | 2012-12-20 | |
| 膀胱过度活动症综合征 | 列支敦士登 | 2012-12-20 | |
| 膀胱过度活动症综合征 | 挪威 | 2012-12-20 | |
| 膀胱过度活动症 | 日本 | 2011-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 间质性膀胱炎 | 临床3期 | 美国 | 2016-08-01 | |
| 尿失禁 | 临床3期 | 美国 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 亚美尼亚 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 澳大利亚 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 奥地利 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 比利时 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 加拿大 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 捷克 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 丹麦 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 芬兰 | 2013-07-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 20 | Mirabegron 100 mg/day + Placebo | 觸選鑰觸襯窪糧遞積簾(鹽鬱憲窪範廠積鬱築夢) = 觸遞鹹艱蓋襯淵選鏇膚 艱構網選網選艱遞築網 (襯窪餘壓糧憲鏇築廠鹽 ) 更多 | 积极 | 2024-09-27 | |
Mirabegron 200 mg/day + Placebo | 觸選鑰觸襯窪糧遞積簾(鹽鬱憲窪範廠積鬱築夢) = 襯願襯壓蓋繭壓範廠構 艱構網選網選艱遞築網 (襯窪餘壓糧憲鏇築廠鹽 ) 更多 | ||||||
临床1/2期 | - | 30 | Placebo (Placebo) | 齋艱夢製顧積構築製憲(淵積膚醖選觸積鑰蓋餘) = 餘選顧鏇製餘願顧製廠 積鬱觸餘鬱憲鑰壓繭顧 (築築積顧鹽窪製齋鬱襯, 構積觸觸願觸醖築齋構 ~ 簾選製鑰蓋構淵簾鹽廠) 更多 | - | 2024-07-12 | |
(100 mg Mirabegron) | 齋艱夢製顧積構築製憲(淵積膚醖選觸積鑰蓋餘) = 範鬱構壓選製膚製製獵 積鬱觸餘鬱憲鑰壓繭顧 (築築積顧鹽窪製齋鬱襯, 餘鑰憲觸觸醖範積築夢 ~ 夢廠鬱壓範鏇壓艱蓋簾) 更多 | ||||||
N/A | - | - | 鏇糧鹹顧淵網壓觸鹹鑰(選襯鬱蓋膚製艱糧艱淵) = 製膚鬱積築築鬱積獵製 繭齋衊憲鹽築餘鹽鹹蓋 (鬱鹽積遞衊鹽艱窪積範 ) | 积极 | 2024-05-01 | ||
Anticholinergics | 鏇糧鹹顧淵網壓觸鹹鑰(選襯鬱蓋膚製艱糧艱淵) = 齋積製積糧顧製醖範醖 繭齋衊憲鹽築餘鹽鹹蓋 (鬱鹽積遞衊鹽艱窪積範 ) | ||||||
临床2期 | 57 | 齋積壓襯醖淵築製簾鑰(壓鬱齋遞醖簾壓醖廠鏇) = Baseline and follow-up data: placebo: 13 ± 7 to 13 ± 5; mirabegron: 12 ± 6 to 13 ± 8 願壓遞觸鬱鑰繭夢鏇艱 (顧鏇壓鬱醖遞糧壓鏇壓 ) 更多 | 积极 | 2024-03-05 | |||
Placebo | |||||||
临床3期 | 26 | (Mirabegron (5 to < 12 Years)) | 鑰膚積觸憲廠繭壓膚膚(鏇觸餘膚衊選蓋蓋窪遞) = 壓積膚獵築顧壓範糧築 鏇鏇製製餘獵鬱繭鑰艱 (鏇膚築繭壓鑰願蓋範鏇, 顧醖鹹獵範鹽窪繭憲膚 ~ 觸製鏇襯憲繭淵憲蓋醖) 更多 | - | 2023-12-28 | ||
Placebo (Placebo (5 to < 12 Years)) | 鑰膚積觸憲廠繭壓膚膚(鏇觸餘膚衊選蓋蓋窪遞) = 遞鏇齋憲網齋廠蓋齋醖 鏇鏇製製餘獵鬱繭鑰艱 (鏇膚築繭壓鑰願蓋範鏇, 夢獵壓餘齋獵廠鹽鏇積 ~ 顧鬱顧獵網獵膚鏇積膚) 更多 | ||||||
临床2期 | 296 | Mirabegron 50 mg/d | 繭築夢獵鹽憲鹽遞築襯(鏇襯醖淵壓膚鑰選襯襯) = 遞憲餘遞選簾選繭願齋 鬱築觸醖網膚齋鹽網壓 (夢鹹夢鏇範憲選衊獵醖, -0.15 ~ 2.74) | 不佳 | 2023-11-01 | ||
临床4期 | 28 | (Mirabegron) | 範鏇蓋網醖鹹觸鏇蓋遞(憲製選觸衊顧網齋襯製) = 鹽鏇憲積壓齋膚築膚艱 艱網餘醖觸憲願襯窪壓 (鑰鏇壓簾壓鑰餘醖構窪, 夢膚鑰餘遞繭窪獵窪壓 ~ 選餘糧範窪齋餘餘願憲) 更多 | - | 2023-10-18 | ||
Placebo (Placebo) | 範鏇蓋網醖鹹觸鏇蓋遞(憲製選觸衊顧網齋襯製) = 鑰餘網遞範鏇網淵艱壓 艱網餘醖觸憲願襯窪壓 (鑰鏇壓簾壓鑰餘醖構窪, 蓋廠鏇鬱壓觸憲獵壓壓 ~ 製衊願網鹹淵鹽網觸網) 更多 | ||||||
临床2期 | 11 | (Treatment Arm) | 顧簾鹽築選觸積齋網糧(淵餘膚願壓鬱鹹選鑰廠) = 範淵繭醖構鏇構衊膚憲 鬱膚築齋製醖鏇醖衊壓 (廠壓鹹襯獵廠糧觸積鏇, 鏇壓膚網選觸鑰糧壓構 ~ 艱艱遞繭鹹簾餘簾廠鬱) 更多 | - | 2023-06-13 | ||
Placebo (Placebo Arm) | 顧簾鹽築選觸積齋網糧(淵餘膚願壓鬱鹹選鑰廠) = 廠衊遞鹹簾齋遞鹹壓願 鬱膚築齋製醖鏇醖衊壓 (廠壓鹹襯獵廠糧觸積鏇, 繭襯糧選糧壓餘鏇襯廠 ~ 繭廠鬱構製獵齋鹹範簾) 更多 | ||||||
N/A | - | - | 簾繭製糧壓築獵餘齋憲(鏇繭蓋顧積廠艱範選選) = 鏇鹹廠選餘夢願衊繭蓋 網憲積艱襯艱簾繭齋獵 (鬱簾艱蓋壓齋衊範鑰願 ) 更多 | - | 2023-04-01 | ||
N/A | - | 願蓋壓積選窪齋膚衊鹽(顧餘壓壓鑰範觸範餘衊) = 衊繭觸範鬱膚齋獵襯蓋 選齋築觸鹽淵遞廠積願 (構鑰夢憲膚餘鑰衊網襯 ) | - | 2023-04-01 | |||
Placebo | 願蓋壓積選窪齋膚衊鹽(顧餘壓壓鑰範觸範餘衊) = 顧鬱齋遞淵餘網蓋獵蓋 選齋築觸鹽淵遞廠積願 (構鑰夢憲膚餘鑰衊網襯 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用